← Russell 3000 cross-section

ANGO ANGIODYNAMICS INC

Trailing twelve months to 2026-05-31 · as filed 2026-07-14, not restated
Healthcare

Scale

Market cap
$655m
Revenue TTM
$320m
Net income TTM
$-37m
Free cash flow
$0m
Composite score
47.6
Sector rank
#2265

Valuation

P / E
EV / EBITDA
EV / sales
1.9
FCF yield
0.08%
Earnings yield vs 10-yr
-10.33pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-11.5%
EBITDA margin
ROE
-21.5%
ROIC
-34.1%
Revenue growth
9.5%

Insider activity, last 90 days

Net open-market
$-0.34m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Our sales and profitability growth also depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. We sell our products in the United States primarily through a direct sales force, and outside the U.S. mainly through distributor relationships. Our Med Device revenue grew by 1.2% in the third quarter of fiscal year 2026 driven by growth in the Core and Venous product lines which was partially offset by softness in the Ports. …ANGIODYNAMICS INC, 10-Q, period ended 2026-02-28, filed 2026-04-02

Read the full passage →